Qiji Investment Successfully Closes First Tranche of RMB 900 Million for Its Series II RMB Fund

Qiji Investment’s RMB Fund II Successfully Completed Its First Close on November 30, 2025, Raising RMB 900 MillionAmidst market cycle fluctuations and numerous uncertainties, the Qiji team has achieved rapid counter-cyclical growth by leveraging its deep industry insights and robust execution capabilities. This progress has earned high recognition and long-term trust from investors, establishing Qiji’s professional reputation in healthcare investment and strengthening its core ability to continuously attract high-quality capital. The successful first close lays a solid foundation for Qiji’s future investment strategy and value creation.

We are grateful for the strong support from a diverse range of investors during the first closing of Fund II, including Shanghai State-owned Capital Venture Guidance Fund, district-level state-owned enterprises in Shanghai, prominent angel investor fund-of-funds, leading pharmaceutical companies, and top-tier family offices. The establishment of this diversified limited partner (LP) structure not only provides a solid capital foundation for the fund but also clearly reflects the high recognition from various market participants of Qiji Investment’s professional capabilities and long-term growth prospects. This collaborative effort will inject robust momentum into the fund’s sustained and steady growth.

Qiji Phase II will continue to deepen its focus on the healthcare and life sciences sectors driven by cutting-edge global technologies, anchoring investments in source innovations with global competitiveness, leading industrial value creation through differentiated strategies, and promoting the continuous advancement of healthcare.

Continuously building a “sharpshooter”-level investment team and establishing a precise investment system have always been the strategic priorities of Qiji Investment. The founding managing partner brings 20 years of executive experience at multinational corporations in both China and the United States, as well as healthcare investment expertise from top-tier funds. With a deep understanding of industry pain points and capital logic, he is an entrepreneur who combines a scientist’s perspective with an investor’s intuition. The core management team has an average of 20 years of industry experience, with backgrounds spanning global healthcare giants, leading research institutions, top-tier funds, and industrial incubators, achieving diverse complementarity and deep integration. This diversified and complementary team background lays a solid foundation for Qiji Investment’s multi-dimensional investment decision-making.

In the investment practice of Qiji Phase I Fund, the team has successfully led investments in a series of entrepreneurial ventures founded by renowned entrepreneurs and scientists in key sectors and important markets. These include Xinthera/Raythera (led by Dr. Dong Qing, former Chief Scientist of Hengrui Medicine), Xiaolu Bio/Tuosheng Pharma (led by Dr. Liu Yongjun, former Global Head of R&D at Sanofi), Ailiana (led by Academician He Chuan, a tenured professor at the University of Chicago and a world-class expert in post-transcriptional modifications), Prost (led by Dr. Chen Shuhui, former Chief Scientist of WuXi AppTec), Zeling Biopharma (led by Professor Chen Lijuan from West China Hospital of Sichuan University, whose core product has entered pivotal Phase III clinical trials), and Amboning (Qiji Investment’s first majority-controlled incubated project), among other innovative enterprises. Significant progress has been achieved in these investments, further validating and reinforcing Qiji Investment’s consistent philosophy: to support, accompany, and empower leading entrepreneurs and scientists in their startups, focus on source innovation, deepen ecosystem enablement, ensure steady and long-term growth through market cycles, and continuously create miracles.

Since its inception, Qiji Investment has consistently earned high acclaim from the market and authoritative institutions, thanks to its impressive investment performance and profound industry influence. It has been honored with awards such as the “Top 20 in Healthcare and Wellness” by Limited Partners Weekly, the “Top 50 Best Early-Stage Venture Capital Firms in China” by CVSource, and the “Best Return Venture Capital Firm” by Zero2IPO Research. Ms. Zhang Li, the founder, has also been repeatedly recognized by industry media as one of the “Best Female Investors in China” for her exceptional leadership and keen investment acumen. Upholding its core values of “Uniting Talent to Benefit Society, Collaborating for Mutual Win, Standing Together Through Thick and Thin, and Creating Miracles,” Qiji Investment is committed to providing comprehensive empowerment to both investors and portfolio companies, creating synergistic value, fostering medical innovation, and jointly pursuing a promising future for the industry.

Qiji Investment is a professional investment firm specializing in early-stage investments in the healthcare and medical sector. The founding team has deep expertise in the medical and biotechnology fields, with extensive experience in healthcare investment at top-tier domestic funds and comprehensive industry chain experience at leading global multinational pharmaceutical companies.

Qiji Investment primarily focuses on high-quality investment opportunities in fields driven by cutting-edge technologies, such as biopharmaceuticals, medical devices, and in vitro diagnostics. It targets niche sectors with significant competitive advantages, with a particular emphasis on the global healthcare market and patients’ “unmet needs.” Committed to empowering portfolio companies and creating synergistic value, Qiji Investment works collaboratively to advance medical innovation and generate value for society.